Progenics Pharmaceuticals, Inc. (PGNX) said Wednesday that it is offering to sell shares of its common stock pursuant to an effective registration statement in an underwritten public offering.
Progenics also plans to grant the underwriter a 30-day option to purchase additional shares of common stock.
All of the shares to be sold in the offering are to be sold by Progenics, with the proceeds to be used for research and development and general corporate purposes.
Jefferies & Company, Inc. is acting as sole book-running manager for the proposed offering.
For comments and feedback: editorial@rttnews.com